Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong
07:00am, Thursday, 31'st Aug 2023
Artificial Intelligence ( AI ) has received incredible attention this year due to the public release of OpenAI's ChatGPT. Its profound capabilities have successfully captured the imaginations of a s
Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?
06:12am, Thursday, 31'st Aug 2023
Johnson & Johnson is cutting its drug development efforts for infectious diseases. It hasn't said anything about ceasing sales of its products on the market.
2 Dividend Kings That Face Massive Legal Risks
05:37am, Thursday, 31'st Aug 2023
3M and Johnson & Johnson have been increasing their dividend payments for decades. They offer above-average dividend yields, with 3M paying as much as 6%.
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?
05:30am, Thursday, 31'st Aug 2023
Three of Johnson & Johnson's blockbusters are on Medicare's price negotiation list. Drugmakers have filed court cases fighting the government's plan to directly negotiate prices.
Medicare's First Price Negotiation List Targets Expensive Drugs (Revised)
04:31am, Thursday, 31'st Aug 2023
The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.
Set and Forget: 3 Dividend Stocks Perfect for Your IRA
05:36pm, Wednesday, 30'th Aug 2023
Dividend stocks provide essential passive income for many investors. For those heading into retirement, this is especially true.
Medicare drug price negotiations may have a muted impact on drugmakers in the near term
01:48pm, Wednesday, 30'th Aug 2023
Many of the drugs are already facing strong competition from other branded medications or patent expirations that will open the market to generic alternatives.
Johnson & Johnson Forecasts Double-Digit Earnings Growth After Kenvue Spin-Off
12:50pm, Wednesday, 30'th Aug 2023
Johnson & Johnson (JNJ) on Wednesday released its first earnings forecast as a standalone pharmaceutical and medical devices company, estimating double-digit growth in earnings this year.
J&J, India's Lupin cut prices for tuberculosis drug in lower-income countries
10:16am, Wednesday, 30'th Aug 2023
Johnson & Johnson and Indian drugmaker Lupin will supply their versions of the tuberculosis drug bedaquiline at a significantly cheaper price in low- and middle-income countries, a global anti-tubercu
Johnson & Johnson sets out new guidance after Kenvue split
07:42am, Wednesday, 30'th Aug 2023
Johnson & Johnson (NYSE:JNJ) has released new financial results for previous quarters that strip out the consumer-health unit that was recently hived off into a new company called Kenvue. J&J, which i
Johnson & Johnson Maintains Dividend After Kenvue Spinout
07:40am, Wednesday, 30'th Aug 2023
Johnson & Johnson maintains its quarterly dividend of $1.19 a share after spinning out consumer-health company Kenvue, although it lowers its earnings and sales projections.
J&J revises 2023 sales, profit outlook lower after Kenvue separation, will maintain dividend
06:50am, Wednesday, 30'th Aug 2023
Johnson & Johnson JNJ, +0.01% updated on Wednesday its 2023 financial guidance in the wake of the Kenvue Inc. KVUE, -0.48% separation that was completed last week. The drug maker now expects full-year
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
05:00pm, Tuesday, 29'th Aug 2023
The Biden Administration just announced the 10 drugs that will be first included in Medicare price negotiations. Several big drugmakers could be affected, with Johnson & Johnson and Bristol Myers Squi
Cantor's Louise Chen breaks down new Medicare drug pricing negotiations
03:02pm, Tuesday, 29'th Aug 2023
Louise Chen, Cantor Fitzgerald, joins 'Power Lunch' to discuss Medicare drug priced ahead of Biden's news conference on the negotiations.
J&J (JNJ) Seeks Full FDA Nod for Balversa in Urothelial Cancer
02:17pm, Tuesday, 29'th Aug 2023
J&J (JNJ) submits a supplemental new drug application to the FDA for full approval of Balversa to treat urothelial carcinoma.
